AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35573797 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score categorization: low risk (0-2 points), moderate risk (3-4 points), high risk (5-7 points).
Number of subjects: 1054
Study 35573797 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive scoring system using clinical factors and CD8+ T cell count.
Number of subjects: 1054
Study 33656446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel IA design
Number of subjects: 215
Study 33656446 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix IA design
Number of subjects: 215
Study 33656446 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical IA design
Number of subjects: 215
Study 33656446 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 215
Study 33656446 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge gain
Number of subjects: 215
Study 35648299 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected ER+ tumours
Number of subjects: 62378
Study 35648299 — intervention group
Group type: COMPARATOR
Intervention: Most deprived quintile
Number of subjects: 62378
Study 35648299 — intervention group
Group type: COMPARATOR
Intervention: Luminal A tumours in the most deprived quintile
Number of subjects: 62378
Study 35648299 — intervention group
Group type: COMPARATOR
Intervention: HER2−enriched tumours in the most deprived quintile
Number of subjects: 62378
Study 35648299 — intervention group
Group type: COMPARATOR
Intervention: Luminal B and TNBC tumours in the most deprived quintile
Number of subjects: 62378
Study 34043229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 34043229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5mg
Number of subjects: 150
Study 34043229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5mg
Number of subjects: 150
Study 34043229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5mg titrated to 5mg
Number of subjects: 150
Study 34043229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug
Number of subjects: 150
Study 32152886 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 34
Study 32152886 — intervention group
Group type: COMPARATOR
Intervention: Indirect laryngoscopy
Number of subjects: 34
Study 34997371 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% SF6
Number of subjects: 159
Study 34997371 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% C2F6
Number of subjects: 159
Study 34997371 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% C3F8
Number of subjects: 159
Study 33787584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol) 100,000 IU
Number of subjects: 191
Study 33787584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 32799994 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy interventions
Number of subjects: 0
Study 32799994 — intervention group
Group type: COMPARATOR
Intervention: Expert opinion
Number of subjects: 0
Study 32799994 — intervention group
Group type: COMPARATOR
Intervention: Case series
Number of subjects: 0
Study 32799994 — intervention group
Group type: COMPARATOR
Intervention: Case-controlled studies
Number of subjects: 0
Study 32799994 — intervention group
Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 0
Study 32762632 — intervention group
Group type: EXPERIMENTAL
Intervention: Labral repair/refixation
Number of subjects: 12
Study 32762632 — intervention group
Group type: COMPARATOR
Intervention: Rim trimming
Number of subjects: 12
Study 32762632 — intervention group
Group type: COMPARATOR
Intervention: Separated CLJ (CLJ Cut group)
Number of subjects: 12
Study 35487873 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G +3142GG genotype in alloimmunized patients with antibodies against Rh and Kell antigens
Number of subjects: 213
Study 35487873 — intervention group
Group type: COMPARATOR
Intervention: HLA-G +14 bp Ins/Del and +3142 C>G variations
Number of subjects: 213
Study 33420472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut-enriched low-calorie diet (NELCD)
Number of subjects: 67
Study 33420472 — intervention group
Group type: COMPARATOR
Intervention: Nut-free low-calorie diet (NFLCD)
Number of subjects: 67
Study 32423746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidian neurectomy
Number of subjects: 112
Study 34031332 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted emmetropia (EM) group
Number of subjects: 139
Study 34031332 — intervention group
Group type: COMPARATOR
Intervention: Predicted residual myopia (RM) group
Number of subjects: 139
Study 33867409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4018
Study 33867409 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 4018
Study 35329235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3x/week, moderate-intensity)
Number of subjects: 30
Study 35329235 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretching and breathing (control)
Number of subjects: 30
Study 35067719 — intervention group
Group type: EXPERIMENTAL
Intervention: TTA-121 6 U/day
Number of subjects: 109
Study 35067719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 34787727 — intervention group
Group type: EXPERIMENTAL
Intervention: Judo
Number of subjects: 65
Study 34787727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball games (soccer, volleyball, handball, basketball)
Number of subjects: 65
Study 36143896 — intervention group
Group type: EXPERIMENTAL
Intervention: McConnell taping
Number of subjects: 52
Study 36143896 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 52
Study 34007136 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography radiomics model
Number of subjects: 185
Study 34007136 — intervention group
Group type: COMPARATOR
Intervention: Image features
Number of subjects: 185
Study 32698912 — intervention group
Group type: EXPERIMENTAL
Intervention: Calanus finmarchicus oil (CO) 2g daily providing 124 mg stearidonic acid, 109 mg EPA, and 87 mg DHA
Number of subjects: 72
Study 32698912 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (Control group)
Number of subjects: 72
Study 35048203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 50
Study 35048203 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 50
Study 34175784 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus naltrexone
Number of subjects: 47
Study 34175784 — intervention group
Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 47
Study 34175784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 32470710 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa2b (PEG-IFNα-2b) at 3 μg/kg/week subcutaneously for 2 years
Number of subjects: 112
Study 32470710 — intervention group
Group type: COMPARATOR
Intervention: observation
Number of subjects: 112
Study 32470710 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa2b (PEG-IFNα-2b)
Number of subjects: 112
Study 34765950 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 (60 mg daily for 3 weeks or 40 mg daily for 2 weeks)
Number of subjects: 145
Study 34765950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 33176853 — intervention group
Group type: EXPERIMENTAL
Intervention: Making Mindfulness Matter (M3) intervention, delivered online over 8 weeks.
Number of subjects: 100
Study 33176853 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group, no intervention during the 8 weeks.
Number of subjects: 100
Study 33543381 — intervention group
Group type: COMPARATOR
Intervention: Subgingival debridement (SD) alone
Number of subjects: 48
Study 33543381 — intervention group
Group type: COMPARATOR
Intervention: Subgingival debridement (SD) with light-activated disinfection (LAD)
Number of subjects: 48
Study 33543381 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival debridement (SD) with light-activated disinfection (LAD) plus probiotic treatment
Number of subjects: 48
Study 34797439 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly warm (iTS=1, n=50)
Number of subjects: 105
Study 34797439 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-to-hot (iTS=2/3, n=44)
Number of subjects: 105
Study 34797439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral (iTS=0, n=11)
Number of subjects: 105
Study 34797439 — intervention group
Group type: COMPARATOR
Intervention: Control condition (15.8 ± 1.2 °C, 55 ± 6% RH)
Number of subjects: 105
Study 34797439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokyo condition (31.6 ± 1.0 °C, 74 ± 5% RH)
Number of subjects: 105
Study 32924566 — intervention group
Group type: EXPERIMENTAL
Intervention: Group $5/$5
Number of subjects: 1500
Study 32924566 — intervention group
Group type: EXPERIMENTAL
Intervention: Group $5/$10
Number of subjects: 1500
Study 32924566 — intervention group
Group type: EXPERIMENTAL
Intervention: Group $10/$0
Number of subjects: 1500
Study 32924566 — intervention group
Group type: EXPERIMENTAL
Intervention: Group $10/$5
Number of subjects: 1500
Study 32924566 — intervention group
Group type: EXPERIMENTAL
Intervention: Group $10/$10
Number of subjects: 1500
Study 32924566 — intervention group
Group type: EXPERIMENTAL
Intervention: Second incentives (various amounts)
Number of subjects: 1500
Study 33839586 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and eating disorder prevention interventions
Number of subjects: 364
Study 33839586 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 364
Study 35118795 — intervention group
Group type: EXPERIMENTAL
Intervention: mi. spot (n=22)
Number of subjects: 41
Study 35118795 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (n=19)
Number of subjects: 41
Study 32379634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 80
Study 32379634 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 80
Study 32921680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day add-on
Number of subjects: 78
Study 32921680 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy add-on
Number of subjects: 78
Study 36153496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab maintenance therapy with thoracic radiotherapy (TRT)
Number of subjects: 104
Study 36153496 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab maintenance therapy without thoracic radiotherapy (TRT)
Number of subjects: 104
Study 32017598 — intervention group
Group type: EXPERIMENTAL
Intervention: VL10%
Number of subjects: 25
Study 32017598 — intervention group
Group type: COMPARATOR
Intervention: VL30%
Number of subjects: 25
Study 34991570 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS
Number of subjects: 166
Study 34991570 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS + SDMT
Number of subjects: 166
Study 34991570 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 166
Study 33446564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-059)
Number of subjects: 191
Study 33446564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-061)
Number of subjects: 191
Study 33446564 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-061)
Number of subjects: 191
Study 33446564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-062)
Number of subjects: 191
Study 33446564 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-062)
Number of subjects: 191
Study 35926795 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.06% bupivacaine
Number of subjects: 180
Study 35926795 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI
Number of subjects: 180
Study 35926795 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI + PCEA with 0.06% bupivacaine
Number of subjects: 180
Study 35926795 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 180
Study 34185259 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously every 3–4 weeks for about 6 months and then every 3 months for a total treatment duration of 5 years
Number of subjects: 4509
Study 34185259 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously
Number of subjects: 4509
Study 33032163 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation‐restricted environmental stimulation therapy (floatation‐REST)
Number of subjects: 9
Study 33032163 — intervention group
Group type: COMPARATOR
Intervention: Control (no floatation‐REST)
Number of subjects: 9
Study 33032163 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation‐REST
Number of subjects: 9
Study 34170235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-communicated management
Number of subjects: 200
Study 34170235 — intervention group
Group type: COMPARATOR
Intervention: Physician-led management
Number of subjects: 200
Study 34481724 — intervention group
Group type: EXPERIMENTAL
Intervention: NSS-2 BRIDGE device (NBD)
Number of subjects: 18
Study 34481724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 34298028 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 918
Study 34298028 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing-text messages (SMS)
Number of subjects: 918
Study 34298028 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 918
Study 32174571 — intervention group
Group type: EXPERIMENTAL
Intervention: Split conjunctival autograft with limbus to limbus orientation (Group 1)
Number of subjects: 192
Study 32174571 — intervention group
Group type: COMPARATOR
Intervention: Split conjunctival autograft without limbus to limbus orientation (Group 2)
Number of subjects: 192
Study 32174571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 192
Study 34159460 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-low volume polyethylene glycol (PEG) for 3 days followed by low volume PEG on examination day
Number of subjects: 250
Study 34159460 — intervention group
Group type: COMPARATOR
Intervention: Senna laxative for 3 days followed by low volume PEG on examination day
Number of subjects: 250
Study 34159460 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-low volume polyethylene glycol (PEG)
Number of subjects: 250
Study 34159460 — intervention group
Group type: COMPARATOR
Intervention: Senna laxative
Number of subjects: 250
Study 34521554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk
Number of subjects: 442
Study 34521554 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1-5 q3wk
Number of subjects: 442
Study 33200180 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-related interventions (diet and/or behavioral manipulation, provision of foods or entire meals, or delivery of dietary components in individual food items or supplements)
Number of subjects: 0
Study 33200180 — intervention group
Group type: EXPERIMENTAL
Intervention: Human nutrition RCTs
Number of subjects: 0
Study 34124999 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time tailored information on vaccination schedule
Number of subjects: 534
Study 34124999 — intervention group
Group type: COMPARATOR
Intervention: Generic information on vaccination schedule
Number of subjects: 534
Study 33878954 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy plus pembrolizumab
Number of subjects: 0
Study 33878954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy followed by pembrolizumab
Number of subjects: 0
Study 33878954 — intervention group
Group type: COMPARATOR
Intervention: Standard of care adjuvant platinum-based chemotherapy
Number of subjects: 0
Study 33009045 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment via CCRAT
Number of subjects: 230
Study 33009045 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 230
Study 33066601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise music trial (T2)
Number of subjects: 20
Study 33066601 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous music trial (T3)
Number of subjects: 20
Study 33066601 — intervention group
Group type: COMPARATOR
Intervention: Non-music trial (T1)
Number of subjects: 20
Study 35238401 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (target‐controlled total intravenous anaesthesia with propofol and remifentanil)
Number of subjects: 60
Study 35238401 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (bilateral scalp block with remifentanil sedation if required)
Number of subjects: 60
Study 35238401 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 60
Study 35238401 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 60
Study 35948843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 79
Study 35948843 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 79
Study 35948843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 34312943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis C‐3102 supplemented milk replacer
Number of subjects: 12
Study 34312943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Bacillus subtilis C‐3102)
Number of subjects: 12
Study 35292486 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour training for neurologists on how to provide complex information about MS escalation therapy
Number of subjects: 34
Study 32788041 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous border plating (± hook)
Number of subjects: 24
Study 32788041 — intervention group
Group type: COMPARATOR
Intervention: Supraspinatus fossa plating (± hook)
Number of subjects: 24
Study 32788041 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the lateral plate hook
Number of subjects: 24
Study 35300506 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine add-on therapy and Budesonide nasal spray
Number of subjects: 66
Study 35300506 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast add-on therapy and Budesonide nasal spray
Number of subjects: 66
Study 35300506 — intervention group
Group type: COMPARATOR
Intervention: Intranasal Budesonide spray with placebo tablet (Control)
Number of subjects: 66
Study 35738244 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of Dialectical Behavior Therapy (DBT-6)
Number of subjects: 240
Study 35738244 — intervention group
Group type: COMPARATOR
Intervention: 12 months of Dialectical Behavior Therapy (DBT-12)
Number of subjects: 240
Study 32667270 — intervention group
Group type: EXPERIMENTAL
Intervention: MACI
Number of subjects: 21
Study 32667270 — intervention group
Group type: COMPARATOR
Intervention: ACI-P
Number of subjects: 21
Study 32667270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 35062872 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA) group
Number of subjects: 103
Study 35062872 — intervention group
Group type: COMPARATOR
Intervention: Multimodal analgesia (MMA) group
Number of subjects: 103
Study 33823285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova‐T) 0.3 mg/kg every 6 weeks (omitted every third cycle)
Number of subjects: 748
Study 33823285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study 33823285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova‐T)
Number of subjects: 748
Study 32645213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (maximum dose = 12 mg/d)
Number of subjects: 858
Study 36167895 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 1.2 mmol L‐1
Number of subjects: 6
Study 36167895 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 2.4 mmol L‐1
Number of subjects: 6
Study 36167895 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 3.6 mmol L‐1
Number of subjects: 6
Study 36167895 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at 1.2, 2.4, and 3.6 mmol L‐1
Number of subjects: 6
Study 36167895 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon (Si) at all concentrations (1.2, 2.4, and 3.6 mmol L‐1)
Number of subjects: 6
Study 33821932 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Patient Information Leaflet (PIL)
Number of subjects: 203
Study 33821932 — intervention group
Group type: COMPARATOR
Intervention: Positively framed Patient Information Leaflet (PIL)
Number of subjects: 203
Study 32083357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute CO2 stimulus duration
Number of subjects: 18
Study 32083357 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute CO2 stimulus duration
Number of subjects: 18
Study 32083357 — intervention group
Group type: COMPARATOR
Intervention: 4-minute CO2 stimulus duration
Number of subjects: 18
Study 32083357 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute CO2 stimulus duration
Number of subjects: 18
Study 32083357 — intervention group
Group type: EXPERIMENTAL
Intervention: VE-CO2 sensitivity from 1-minute to 4- and 5-minute durations
Number of subjects: 18
Study 32083357 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-minute and 5-minute steady-state time-points
Number of subjects: 18
Study 36419123 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at 150 µg/m3 PM2.5 for 4 hours
Number of subjects: 17
Study 36419123 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 17
Study 36419123 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at varying concentrations (20, 50, 150 µg/m3 PM2.5)
Number of subjects: 17
Study 32540235 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane
Number of subjects: 0
Study 32540235 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 0